Disclosure context

About Incransom

Incransom is a ransomware group that emerged in August 2023, operating with primarily financial motivations as evidenced by their targeting of high-value sectors across multiple developed nations. The group's origin and specific affiliations remain undocumented by major threat intelligence organizations, though their operational patterns suggest they likely operate independently rather than as a ransomware-as-a-service model. With 734 documented victims, Incransom has demonstrated a preference for targeting organizations in the United States, Canada, United Kingdom, Germany, and Australia, with particular focus on healthcare, technology, business services, and manufacturing sectors, though their attack methodology and specific technical capabilities have not been extensively documented by established security researchers or government agencies. The group's notable campaigns and specific high-profile victims have not been publicly detailed by CISA, FBI, Mandiant, or other reputable threat intelligence sources, suggesting either operational security effectiveness or limited visibility into their most significant operations. Based on available intelligence, Incransom appears to remain active as of recent reporting periods, though comprehensive analysis of their current operational status requires additional documentation from established threat intelligence sources. The group has been linked to 805 public disclosures across our corpus. First observed on a leak site on August 9, 2023; most recent post May 19, 2026. The operation is currently active.

Also tracked as: inc ransom.

Timeline of this disclosure

March 25, 2026glenmarkpharma.com listed by Incransomon the group's public leak site

Records: 032. Email

Sector and geography

This disclosure adds to ransomware activity in the Healthcare sector, which has 1,779 disclosures indexed across all operators we track. Geographically, glenmarkpharma.com is reported in India, a country with 255 ransomware disclosures in our corpus.

How we know this. Darkfield monitors public ransomware leak sites continuously, archiving every new disclosure and the data later released against the victim. Each entry on this page is sourced from the operator's own publication and cross-checked against complementary OSINT feeds (RansomLook, ransomware.live, RansomWatch). We do not collect or host stolen data — only the metadata, timestamps and screenshots needed to make the public disclosure searchable and accountable. Records here are corrected when the original post is edited, retracted, or merged with another disclosure.

Ransomware victim disclosure

← All victims

Glenmark Pharmaceuticals

listed as glenmarkpharma.com · Claimed by Incransom · listed 2 months ago

032. Email

Records

56d

Age

since listed · data leaked

Status timeline

Listed
Mar 25, 2026
Data leaked

At a glance

Group: Incransom
Status: Data leaked
Country: India
Sector: Healthcare
Listed on leak site: Mar 25, 2026
Records: 032. Email

About the victim

AI dossier — public-source company profile

Glenmark Pharmaceuticals is a global pharmaceutical company founded in 1977 and headquartered in Mumbai, India. The company develops, manufactures, and markets pharmaceutical products across more than 80 countries, with operations spanning North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. It employs over 16,000 people globally, operates 11 manufacturing facilities and 6 R&D centres, and focuses on innovative and generic medicines across multiple therapeutic areas.

Industry: Pharmaceutical Manufacturing & R&D
Address: Glenmark Pharmaceuticals Ltd., Mumbai, India
Employees: 16000+
Founded: 1977

Attack summary

Severity: high — Data has been published (not merely threatened) by the group, and the leak includes identifiable personal information about named senior executives and corporate contact data from a large publicly listed pharmaceutical company operating globally. The scale of operations and regulatory environment (pharma, SEBI-listed) elevate the impact beyond moderate.

The Incransom group claims to have published data belonging to Glenmark Pharmaceuticals, with the disclosure status marked as data_published. The leaked post includes named senior executives with titles and contact details, as well as investor and compliance contact information, suggesting exfiltration of internal corporate and personnel data.

high

Data the group says was taken

AI dossier — extracted from the leak post

Senior executive names and titles
Executive contact details
Investor compliance officer contact information
Corporate email addresses
Telephone and fax numbers
Registrar and share transfer agent details

What the group claims

Glenmark Pharmaceuticals, founded in 1977 and headquartered in Mumbai, India, is a global pharmaceutical company that develops, manufactures, and markets pharmaceutical products. The company operates in over 25 countries across North America, South America, Europe, Asia, Africa, and the Middle East, with a strong focus on research and development of innovative medications. Glenmark specializes in various therapeutic areas and maintains a diverse portfolio of pharmaceutical products serving both business and consumer markets worldwide. Rajeev Sharma Senior Vice President and Chief Financial Officer - North America Laura Lester Senior Vice President & General Counsel - North America Jim Brown Senior Vice President Firas B Abulaban Senior Vice President and Corporate Quality Head of North America Bradley Nowels Vice President Institutional Sales – North America Vishal Arora Vice President of Business Development and Licensing Michael Pope Executive Director and Site Head – Monroe, NC Adam Subervi Chief Compliance Officer Fabio Moreno Executive Director and Head of the OTC Business Kathleen (Kathy) McKenna Senior Director – Human Resources INVESTORS Company Secretary & Compliance Officer [email protected] Tel No.: +91 22 4018 9999 Fax No.: +91 22 4018 9986 REGISTRAR AND SHARE TRANSFER AGENTS KFIN Technologies Limited Selenium Building, Tower-B, Plot No 31 & 32,Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy, Telangana, India – 500 032. Email ID: [email protected] Toll Free/ Phone Number : 1800 309 4001 WhatsApp Number : (91) 910 009 4099 KFINTECH Corporate Website: www.kfintech.com RTA Website: https://ris.kfintech.com Investor Support Centre (DIY Link) https://ris.kfintech.com/clientservices/isc BUSINESS DEVELOPMENT For queries related to collaboration and partnership, please email to : [email protected] INVESTORS Company Secretary & Compliance Officer

Sources

Source

Indexed 2 months ago

This page surfaces a public ransomware disclosure indexed by Darkfield. Original posts come from the operator's own leak site; we cross-check against ransomware.live, RansomLook and RansomWatch where applicable. Share this URL freely.